{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:39:49Z","timestamp":1787164789948,"version":"build-2736575974"},"reference-count":17,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      There is no clear pharmacokinetic and pharmacodynamic (PK\/PD) target during vancomycin\u2010susceptible\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>Enterococcus faecium<\/jats:italic>\n                      <\/jats:styled-content>\n                      bacteremia (EFB).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate whether in\u2010hospital mortality was associated with susceptibility to amoxicillin or vancomycin minimum inhibitory concentration (MIC) of the strain and with area under the curve over 24\u2009h (AUC) and AUC\/MIC during EFBs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      All\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>E. faecium<\/jats:italic>\n                      <\/jats:styled-content>\n                      strains isolated from blood cultures performed between January 1, 2017, and December 31, 2022, were included, and clinicobiological data were retrospectively extracted from corresponding medical records. The Vancomycin MICs were estimated using the VITEK 2 automated system. AUC was calculated among patients who received vancomycin during their first episode of EFB with available data.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Two hundred fifteen\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>E. faecium<\/jats:italic>\n                      <\/jats:styled-content>\n                      strains not susceptible to amoxicillin had been isolated in 207 patients (125 male, median age 69 [1\u201398] years) with biliary and digestive tract diseases, hematologic malignancies, or COVID\u201019 in 124 (59.9%), 35 (16.9%), and 17 (8.2%) cases, respectively. The median vancomycin MIC was 0.5 [0.5\u20132] mg\/L, and 67 patients (32.3%) died during the hospitalization. In\u2010hospital mortality was not associated with susceptibility to amoxicillin (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.14) or vancomycin MIC (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.07) of the strain. Neither mean AUC (592.7 versus 521.7mgh\/L) nor mean AUC\/MIC ratio (1066.5 versus 1000.5) was associated with in\u2010hospital mortality (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.17 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.54, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Besides amoxicillin susceptibility and vancomycin MIC of the strain, there was no significant association between in\u2010hospital mortality and vancomycin AUC or AUC\/MIC. Retrospective observational studies focusing on in\u2010hospital mortality among patients with severe comorbidities may not be adequate for the determination of the PK\/PD target of vancomycin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/fcp.70039","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T05:24:43Z","timestamp":1755149083000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["No Impact of Vancomycin MIC, AUC, or AUC\/MIC in\n                    <scp>\n                      <i>Enterococcus faecium<\/i>\n                    <\/scp>\n                    Bacteremia"],"prefix":"10.1111","volume":"39","author":[{"given":"Anne","family":"Limelette","sequence":"first","affiliation":[{"name":"Laboratoire de Bact\u00e9riologie P\u00f4le de Biologie  Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Tromeur","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, Maladies Infectieuses et Immunologie Clinique H\u00f4pital Robert Debr\u00e9  Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Rhaiem","sequence":"additional","affiliation":[{"name":"Service de Chirurgie G\u00e9n\u00e9rale, Digestive et Endocrinienne H\u00f4pital Robert Debr\u00e9  Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Bonnet","sequence":"additional","affiliation":[{"name":"Pharmacie Hospitali\u00e8re H\u00f4pital Robert Debr\u00e9  Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9092-5071","authenticated-orcid":false,"given":"Yohan","family":"N'Guyen","sequence":"additional","affiliation":[{"name":"Consultations de M\u00e9decine Interne, Maladies Infectieuses et Immunologie Clinique H\u00f4pital Robert Debr\u00e9  Reims France"},{"name":"UMR\u2010S 1320 CardioVir. Universit\u00e9 de Reims Champagne Ardenne  Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa036"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010021\u201006809\u2010x"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010022\u201007668\u2010w"},{"key":"e_1_2_11_5_1","unstructured":"European Committee on Antimicrobial Susceptibility Testing \u201cData from the EUCAST MIC distribution website \u201d last accessed 31st March 2025 http:\/\/www.eucast.org."},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01602\u201017"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13091378"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010024\u201010399\u20109"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40780\u2010019\u20100138\u20102"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096\u2010021\u201004313\u20103"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12995"},{"key":"e_1_2_11_12_1","unstructured":"Comit\u00e9 de l'antibiogramme de la Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie \u201cEuropean Committee on Antimicrobial Susceptibility Testing \u201d Guidelines 2021 (April) accessed 31stMarch 2025 https:\/\/www.sfm\u2010microbiologie.org\/wp\u2010content\/uploads\/2021\/04\/CASFM2021__V1.0.AVRIL_2021.pdf."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.2196\/30577"},{"key":"e_1_2_11_14_1","unstructured":"Klick IncandLakeridge Health accessed 31st March 2025 https:\/\/www.vancocalc.com."},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.12.4934\u20104941.2005"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1266-6"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01046\u201007"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0891\u20105520(03)00065\u20105"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.70039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:32:54Z","timestamp":1764509574000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.70039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1111\/fcp.70039"],"URL":"https:\/\/doi.org\/10.1111\/fcp.70039","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"2024-12-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70039"}}